Manufacturer
Actavis Italy S.p.A.
Contents
Daunorubicin HCl
Indication
Monotherapy or in combination w/ other antiblastic for acute myeloblastic leukemia. Promyelocytic & acute lymphoblastic leukemia, neuroblastoma & rhabdomyosarcoma.
Instruction
0.5-3 mg/kg single dose. Repeat doses 0.5-1 mg/kg at ≥1-day intervals, doses 2 mg/kg at ≥4-day intervals & doses 2.5-3 mg/kg at 7-14 days intervals.
Drug interaction
Additive toxicity w/ other cytotoxic drugs. Other potentially cardiotoxic drugs, other cardioactive compd (eg, Ca-channel blockers). Precipitation w/ heparin & Al.
Malaysia
